POSTER PRESENTATIONS

01. Emerging concepts / New Agents

P01.01 - PLAP as Target for cancer immunotherapy - Development and Preclinical Characterization of Bispecific Monoclonal Antibody in Colorectal cancer immunotherapy

Norah Alrishedan, Oxford, United Kingdom

 

P01.02 - Selective induction of cell death in Jurkat cells with recombinant fungal lectin CNL

Milica Perisic Nanut, Ljubljana, Slovenia

 

P01.03 - RNAi mediated PD-1 knockdown induces a TCF-1 positive population in activated human CD8 T cells with stem-like associated marker profile

Anna Herbstritt, Munich, Germany

 

P01.04 - APEX-mediated biotinylation as a potent tool for evaluation of chemokine-receptor interactions and respective binding inhibitors

Antonia Beimert, Munich, Germany

P01.05 - Modelling T Cell migration in 3D vascular beds in a high-throughput microfluidic platform

Luuk de Haan, Oegstgeest, Netherlands

P01.06 - DSP216 blocks HLA-G and CD47 signaling toward immune cells and redesigns the immune suppressive tumor microenvironment

Lisa Jacob, Groningen, Netherlands

P01.07 - Galectin 9 dependent immune evasion machinery as a potential target for personalised immunotherapy of cancer

Vadim Sumbayev, Chatham Maritime, United Kingdom

 

02. Tumor microenvironment and microbiome in Immunotherapy

P02.01 - A bioinformatic analysis: the overexpression and clinical significance of HVEM in liver hepatocellular carcinoma

Kunmin Xiao, Beijing, China

 

P02.02 - Easy and scalable transfer of an immuno-oncology panel across a wide range of cancer tissue types

Pamela Pulimeno, Tolochenaz, Switzerland

 

P02.03 - Organization, function and gene expression of tertiary lymphoid structures in pancreatic cancer resembles lymphoid follicles in secondary lymphoid organs and their abundance is related to superior survival

Jonas Lehmann, Cologne, Germany

 

P02.04 - High-plex spatial immune cell profiling of the tumor microenvironment with ChipCytometry

Thomas Campbell, Saint Louis, United States

 

P02.05 - How proton pump inhibitors blunt immune checkpoint inhibitors efficacy: a role of the microbiome?

Eloïse Ramel, Bordeaux, France

 

P02.06 - Investigating the roles of IL-25 and ILC2s in APC-mutation-mediated colorectal cancer

Jane Murphy, Cambridge, United Kingdom

 

P02.07 - Innate immunity atlas of hepatocellular carcinoma unravels the differentiation hierarchy of myeloid NK cells and MDSCs

Domitille Chalopin, Bordeaux Cedex, France

 

P02.08 - The role of the inflammasome in the spatiotemporal evolution of the immune cell landscape in post-resection glioblastoma

Sébastian Lillo, Bordeaux, France

 

P02.09 - Integrated single-cell profiling dissects cell-state-specific enhancer landscapes of human tumor-infiltrating T cells

Christian Schmidl, Regensburg, Germany

 

03. Vaccine Therapy

P03.01 - Development of a multi-tumour antigen vaccine for hard-to-treat cancers

Carles Puig Saenz, Nottingham, United Kingdom

 

P03.02 - A mutated prostatic acid phosphatase (PAP) peptide-based vaccine induces PAP-specific CD8+ T cells with ex vivo cytotoxic capacities in HHDII/DR1 transgenic mice

Jubini Thomas, Nottingham, United Kingdom

 

P03.03 - Active immunization against human endogenous retrovirus type K (HERV-K) as an immunotherapeutic strategy against solid tumors

Peter Holst, COPENHAGEN, Denmark

 

P03.04 - Combined SCIB1 DNA vaccine and PD-1 checkpoint blockade for the treatment of intracranial tumours

Stephanie McArdle, Nottingham, United Kingdom

 

P03.05 - Vaccine immunotherapy against human endogenous retrovirus: a focus on anti-herv-k antibodies

Amaia V. Bermejo, Copenhagen, Denmark

 

P03.06 - Tumor associated antigens and pathogen antigens: friends or foes

Luigi Buonaguro, NAPOLI, Italy

 

P03.07 - Towards HERV-H Env protein based tumor stratification and intervention strategies

Jasmin Gille, Regensburg, Germany

 

P03.08 - Neoantigenic versus multi-antigenic personalized B16 melanoma vaccines comparison according to anti-tumor T cell response intensity

Ekaterina Ushakova, Moscow, Russian Federation

 

04. Precision Medicine Meets Immunotherapy (Immuno-Monitoring)

P04.01 - Volatile profiling using an eNose allows differentiation of volatile phases derived from serum, DC, or MLC culture supernatants from healthy or leukemic samples

Helga Schmetzer, Munich, Germany

 

P04.02 - A high sensitivity, tumor-informed liquid biopsy platform, designed to detect minimum residual disease at part per million resolution

Maik Pruess, Menlo Park, United States

 

P04.03 - Cancer Immunotherapies, Companion Diagnostics and Precision Medicine

Nora Cascante-Estepa, Bonn, Germany

 

05. Reverse translation

P05.01 - Platelets role in immunotherapy response in non-small cell lung cancer

Chiara Colarusso, Fisciano, Italy

 

06. Cell Therapy in Solid Tumors

P06.01 - ROR1-CAR T-cells as novel treatment strategy for anaplastic thyroid carcinoma

Dmitry Chernyakov, Halle (Saale), Germany

 

P06.02 - Anti-nucleolin CAR (chimeric antigen receptor)-T cell targeting Triple-Negative Breast Cancer - critical parameters in CAR-T cells generation

Teresa Abreu, Coimbra, Portugal

 

P06.03 - T cell mediated killing of neuroblastoma is inhibited by secreted MIF and MDK

Josephine Strijker, Utrecht, Netherlands

 

P06.04 - Immune responses against shared antigens are common in esophago-gastric cancer and can be enhanced using CD40-activated B cells

Martin Thelen, Cologne, Germany

 

07. Cell Therapy in Haematologic Diseases

P07.01 - THE POTENTIAL ROLE OF EXTRACELLULAR VESICLE-DERIVED SMALL RNAs IN AML RESEARCH AS NON-INVASIVE BIOMARKER

Lin Li, München, Germany

 

P07.02 - Control leukemia by inducing anti-cancer immune reactivity in vivo? - Potential of a DC-triggered mechanism

Helga Schmetzer, Munich, Germany

 

08. Combination Therapy

P08.01 - Combined approach of Adoptive Cell Therapy with Cytokine-Induced Killer cells retargeted with immunotools against HER-2-expressing breast cancer

Annavera Ventura, Padova, Italy

 

P08.02 - Liposomal doxorubicin enhances the radiation-induced abscopal effect by promoting the release of mitochondrial DNA

Liqun Wang, Freiburg im Breisgau, Germany

 

P08.03 - Interleukin-12 gene electrotransfer as an adjuvant immunotherapy to electrochemotherapy

Katja Ursic Valentinuzzi, Ljubljana, Slovenia

 

P08.04 - Phototherapy with cancer-specific nanoporphyrin potentiates immunotherapy in bladder cancer

Chong-xian Pan, Boston, United States

 

P08.05 - Lentiviral protein Vpx delivery systems as potential weapons to improve cytarabine treatment response against acute myeloid leukemia

Ramya Nair, Munich, Germany

 

P08.06 - Use of luciferase-labeled target cells to explore immune cell killing in high throughput format

Carla Castro, Freiburg, Germany

 

P08.07 - Identification of stress granule formation as a therapeutic target in chemotherapy treated colorectal cancer

Annalena Renner, Vienna, Austria

 

P08.08 - Immunomodulation by Lactate dehydrogenase C indicates a potential new opportunity for combination therapy

Adviti Naik, Doha, Qatar

 

P08.09 - Genome-wide CRISPR/Cas9 screening for identification of tumor-intrinsic mechanisms of resistance to anti-PD1 therapy in high-risk neuroblastoma

Divya Nagarajan, Uppsala, Sweden

 

P08.10 - Combining STING-agonist with radiotherapy remodels tumor immune microenvironment in human malignant pleural effusions

Rebecca Zirnbauer, Vienna, Austria

 

09. Young Researchers Session

P09.01 - Single-cell transcriptomic atlas-guided development of chimeric antigen-receptor (CAR) T cells for the treatment of acute myeloid leukemia

Adrian Gottschlich, Munich, Germany

 

P09.02 - Modular P329G-binding CAR T cells engineered to recognize human effector-silenced antibodies carrying a P329G Fc-mutation for targeting of solid tumor antigens

Sophia Stock, Munich, Germany

 

P09.03 - Activation of IL-22 signaling correlates with higher CD155 expression and stratifies poor outcomes of early-stage lung and breast cancer patients

Daria Briukhovetska, Munich, Germany

 

P09.04 - Cathepsin V inhibition prevents the activation of cystatin F and increases immune cell cytotoxicity

Emanuela Senjor, Ljubljana, Slovenia

 

P09.05 - Exploring the therapeutic vulnerabilities of cathepsin S hyperactive tumors

Johannes Hildebrand, München, Germany

 

P09.06 - A Toll-Like Receptor agonist represents a potential adjuvant in fourth generation CAR-T cell-based immunotherapy

Jolanda Magri, Candiolo, Italy

 

P09.07 - Deciphering the nature of the cooperation between monocytes/macrophages and CD8+ T cells during immunotherapy-induced tumor regression

Anaïs Vermare, Paris, France

 

P09.08 - The tumor immune microenvironment of head and neck cancer in relation to anatomical site classification

Tara Muijlwijk, Amsterdam, Netherlands

P09.09 - A CAR-T cell-based approach for the treatment of malignant T cell diseases

Maximilian Funk, Vienna, Austria

 

P09.10 - Dysregulated Expressions of Inhibitory Checkpoint Molecules and Their Ligands on T-Cells and Blasts in AML Relapses After Stem Cell Transplantation (SCT)

Sophia Bohlscheid, Munich, Germany

 

P09.11 - Anti-proliferative effects of gut microbial metabolites on human gastric adenocarcinoma cells and their potential synergy with dexamethasone

Deep Jyoti Bhuyan, Penrith, Australia

 

P09.12 - Hereditary homozygosity and allelic imbalance of HLA as common immune escape mechanisms in esophageal adenocarcinoma

Maria Garcia Marquez, Cologne, Germany

 

P09.13 - Immune geospatial profiling and characterization of glioma microenvironment after adoptive cell therapy shows differentially expressed antigen processing and cross-presentation gene signatures

Laura Falceto Font, Gainesville, United States

 

P09.14 - The role of IDO1 and cellular senescence in the efficacy of PD-1 pathway blockade and radiotherapy in aged mice with glioblastoma

Evridiki Asimakidou, Chicago, United States

 

P09.15 - Patient-derived head and neck tumor slice cultures - a versatile tool to study oncolytic virus action

Melissa Mayr, Innsbruck, Austria

 

P09.16 - MelARV vaccine with mutations in the immunosuppressive domain elicits increased immunity and elimination of established tumors in mice

Joana Daradoumis, Copenhagen, Denmark

 

P09.17 - High-resolution of neoantigen-specific T cell receptor activation patterns - moderate stimulation predicts sustained anti-tumor-response

Franziska Füchsl, München, Germany

 

P09.18 - TNF induction in essential for oncolytic influenza A virus induced cancer regression and tumor associated macrophage repolarization

Jakob Homola, Vienna, Austria

 

P09.19 - Complex primary organoid cultures to dissect immunogenic effects of therapy on macrophages in a precision medicine-like approach

Julijan Kabiljo, Wien, Austria

 

P09.20 - Impact of TCR independent, KIR-HLA-C interactions on KIR+CD8+ T cells in health and disease

Janine Kemming, Kongens Lyngby, Denmark

 

P09.21 - Modelling the spatial dynamics of oncolytic virotherapy in the presence of virus-resistant tumor cells

Darshak Bhatt, Groningen, Netherlands

 

P09.22 - Toward a rational design of immunonanotherapies

Vincent Mittelheisser, Strasbourg, France

 

P09.23 - Immune cell infiltration as a novel marker for predicting patient outcome in nephroblastoma

Lukas Watzke, Vienna, Austria